NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR - Currency: USD
We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 233 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
NMR had a negative operating cash flow in the past year.
NMR had positive earnings in each of the past 5 years.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 69.53% of its industry peers.
Looking at the Return On Equity, with a value of 9.82%, NMR is in line with its industry, outperforming 57.94% of the companies in the same industry.
With a Return On Invested Capital value of 0.62%, NMR is not doing good in the industry: 72.53% of the companies in the same industry are doing better.
Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 7.84%.
The last Return On Invested Capital (0.62%) for NMR is above the 3 year average (0.41%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.62% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
1.3 Margins
With a Profit Margin value of 7.19%, NMR is not doing good in the industry: 65.67% of the companies in the same industry are doing better.
NMR's Profit Margin has declined in the last couple of years.
The Operating Margin of NMR (9.96%) is worse than 71.24% of its industry peers.
NMR's Operating Margin has declined in the last couple of years.
NMR's Gross Margin of 39.95% is on the low side compared to the rest of the industry. NMR is outperformed by 65.67% of its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
Compared to 1 year ago, NMR has less shares outstanding
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
Compared to 1 year ago, NMR has an improved debt to assets ratio.
2.2 Solvency
NMR has an Altman-Z score of -0.25. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
NMR has a worse Altman-Z score (-0.25) than 79.83% of its industry peers.
NMR has a Debt/Equity ratio of 10.44. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.44, NMR is not doing good in the industry: 90.13% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.25 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
With a Current ratio value of 0.23, NMR is not doing good in the industry: 88.41% of the companies in the same industry are doing better.
NMR has a Quick Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.23, NMR is not doing good in the industry: 88.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 96.52% over the past year.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
Looking at the last year, NMR shows a quite strong growth in Revenue. The Revenue has grown by 13.94% in the last year.
NMR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%
3.2 Future
NMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.35% yearly.
The Revenue is expected to decrease by -8.82% on average over the next years.
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
NMR is valuated cheaply with a Price/Earnings ratio of 7.94.
NMR's Price/Earnings ratio is rather cheap when compared to the industry. NMR is cheaper than 83.69% of the companies in the same industry.
NMR is valuated cheaply when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 8.33, the valuation of NMR can be described as very reasonable.
Based on the Price/Forward Earnings ratio, NMR is valued cheaper than 83.69% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.90. NMR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.94 | ||
| Fwd PE | 8.33 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than the industry average as 70.39% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.04 |
4.3 Compensation for Growth
NMR's earnings are expected to decrease with -4.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.72
EPS Next 2Y-4.35%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.20%, NMR is a good candidate for dividend investing.
NMR's Dividend Yield is comparable with the industry average which is at 8.00.
Compared to an average S&P500 Dividend Yield of 2.42, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.2% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 33.03% of its income as dividend. This is a sustainable payout ratio.
DP33.03%
EPS Next 2Y-4.35%
EPS Next 3YN/A
NYSE:NMR (7/3/2025, 7:54:10 PM)
6.51
-0.04 (-0.61%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change2.18%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.39B
Analysts69.23
Price Target7.24 (11.21%)
Short Float %0.03%
Short Ratio1.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.2% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.6%
PT rev (3m)-3.33%
EPS NQ rev (1m)0.74%
EPS NQ rev (3m)-65.97%
EPS NY rev (1m)0.74%
EPS NY rev (3m)4.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.94 | ||
| Fwd PE | 8.33 | ||
| P/S | 0.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.81 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 22.04 |
EPS(TTM)0.82
EY12.6%
EPS(NY)0.78
Fwd EY12%
FCF(TTM)-3.61
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS11.03
BVpS8.08
TBVpS8.08
PEG (NY)N/A
PEG (5Y)0.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.58% | ||
| ROIC | 0.62% | ||
| ROICexc | 0.68% | ||
| ROICexgc | 0.69% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
ROICexc(3y)0.45%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.07%
ROCE(5y)1.07%
ROICexcg growth 3Y16.49%
ROICexcg growth 5Y7.83%
ROICexc growth 3Y15.92%
ROICexc growth 5Y7.53%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.25 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year19840.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A